Travere Therapeutics
TVTX
147 hedge funds and large institutions have $1.03B invested in Travere Therapeutics in 2020 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 53 increasing their positions, 40 reducing their positions, and 11 closing their positions.
209% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 11
60% more capital invested
Capital invested by funds: $643M → $1.03B (+$388M)
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
19% more funds holding
Funds holding: 124 → 147 (+23)
3.44% more ownership
Funds ownership: 102.12% → 105.56% (+3.4%)
44% less call options, than puts
Call options by funds: $2.83M | Put options by funds: $5.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$43.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$16.7M |
| 3 |
Renaissance Technologies
New York
|
+$12.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$9.48M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$33.8M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.24M |
| 3 |
AI
Atom Investors
Austin,
Texas
|
-$2.6M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$2.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$685K |
TVTX Hedge Fund Activity: Q2 2020 in Review
147 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2020, worth a combined $1.03B — up 60% from $643M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TVTX positions and 11 closed out — a net gain of 23 holders — while 53 added to existing stakes and 40 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $43.8M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $33.8M sold.
- 147 institutional investors held Travere Therapeutics (TVTX) as of Q2 2020, up from 124 in Q1 2020.
- Funds reported $1.03B of Travere Therapeutics stock for Q2 2020, up 60% quarter-over-quarter.
- 34 funds opened new Travere Therapeutics positions in Q2 2020 and 11 closed out, a net change of +23 holders.
- The largest Travere Therapeutics buyer in Q2 2020 was Janus Henderson Group, an estimated $43.8M added.
- The largest Travere Therapeutics seller in Q2 2020 was Consonance Capital Management, an estimated $33.8M sold.
Based on aggregated 13F filings for Q2 2020.